vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and GLACIER BANCORP, INC. (GBCI). Click either name above to swap in a different company.
GLACIER BANCORP, INC. is the larger business by last-quarter revenue ($306.8M vs $191.2M, roughly 1.6× Axsome Therapeutics, Inc.). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 24.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Glacier Bancorp, Inc. is a regional multi-bank holding company headquartered in Kalispell, Montana, United States. It is a successor corporation to the Delaware corporation originally incorporated in 1990. The company provides personal and commercial banking services from 221 locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, and, Nevada.
AXSM vs GBCI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $306.8M |
| Net Profit | — | $82.1M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 26.8% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $306.8M | ||
| Q4 25 | $196.0M | $306.5M | ||
| Q3 25 | $171.0M | $260.7M | ||
| Q2 25 | $150.0M | $240.6M | ||
| Q1 25 | $121.5M | $222.6M | ||
| Q4 24 | $118.8M | $223.0M | ||
| Q3 24 | $104.8M | $214.9M | ||
| Q2 24 | $87.2M | $198.7M |
| Q1 26 | — | $82.1M | ||
| Q4 25 | $-28.6M | $63.8M | ||
| Q3 25 | $-47.2M | $67.9M | ||
| Q2 25 | $-48.0M | $52.8M | ||
| Q1 25 | $-59.4M | $54.6M | ||
| Q4 24 | $-74.9M | $61.8M | ||
| Q3 24 | $-64.6M | $51.1M | ||
| Q2 24 | $-79.3M | $44.7M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 24.9% | ||
| Q3 25 | -27.0% | 32.7% | ||
| Q2 25 | -24.5% | 27.1% | ||
| Q1 25 | -46.9% | 28.5% | ||
| Q4 24 | -61.1% | 33.0% | ||
| Q3 24 | -59.8% | 28.9% | ||
| Q2 24 | -89.5% | 27.3% |
| Q1 26 | — | 26.8% | ||
| Q4 25 | -14.6% | 20.8% | ||
| Q3 25 | -27.6% | 26.0% | ||
| Q2 25 | -32.0% | 21.9% | ||
| Q1 25 | -48.9% | 24.5% | ||
| Q4 24 | -63.1% | 27.7% | ||
| Q3 24 | -61.7% | 23.8% | ||
| Q2 24 | -91.0% | 22.5% |
| Q1 26 | — | $0.63 | ||
| Q4 25 | $-0.55 | $0.49 | ||
| Q3 25 | $-0.94 | $0.57 | ||
| Q2 25 | $-0.97 | $0.45 | ||
| Q1 25 | $-1.22 | $0.48 | ||
| Q4 24 | $-1.54 | $0.55 | ||
| Q3 24 | $-1.34 | $0.45 | ||
| Q2 24 | $-1.67 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $1.4B |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $4.2B |
| Total Assets | $713.6M | $31.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | $1.4B | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $88.3M | $4.2B | ||
| Q3 25 | $73.7M | $3.6B | ||
| Q2 25 | $73.1M | $3.5B | ||
| Q1 25 | $53.2M | $3.3B | ||
| Q4 24 | $57.0M | $3.2B | ||
| Q3 24 | $92.9M | $3.2B | ||
| Q2 24 | $102.9M | $3.1B |
| Q1 26 | $713.6M | $31.7B | ||
| Q4 25 | $689.8M | $32.0B | ||
| Q3 25 | $669.3M | $29.0B | ||
| Q2 25 | $639.8M | $29.0B | ||
| Q1 25 | $596.7M | $27.9B | ||
| Q4 24 | $568.5M | $27.9B | ||
| Q3 24 | $561.5M | $28.2B | ||
| Q2 24 | $548.2M | $27.8B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
GBCI
| Net Interest Income | $268.7M | 88% |
| Noninterest Income | $38.1M | 12% |
